AlcHepNet

The ITAALD trial is now enrolling patients with sAH. This multicenter, randomized study evaluates IL-22 (F-652) vs prednisone + integrated AUD therapy (acamprosate + counseling) to improve liver & alcohol-related outcomes. Learn more clinicaltrials.gov/study/NCT07060…

New publication out in JHEP Reports from @Bernd_Schnabl and team! 🎉 Peptide YY reduces Candida albicans cytotoxicity in alcohol-associated liver disease—opening new directions for microbiome-targeted therapies. 🔗 jhep-reports.eu/article/S2589-…

@AlcHepNet work in @JAMANetworkOpen led by @LaurenNephewMD @nagachalasani Only 37% of AH pts referred for transplant Neighborhood disadvantage shapes referral - we’re missing pts before they even reach transplant. Referral is key equity leverage point jamanetwork.com/journals/jaman…

Excited to share that the ITAALD trial has been officially launched! This trial is investigating IL-22 followed by AUD tx in severe alcohol-associated hepatitis, building on promising phase 2 results: pubmed.ncbi.nlm.nih.gov/31774566/ @AlcHepNet @NIAAAnews @Dr_Vijay_Shah @juanpabloarab

ITAALD Study now OPEN for enrollment! We’re enrolling sAH patients (MELD 20–35). If you have patients who may qualify, we’d love to connect. Active sites: IU, VCU, UTSW, Cleveland Clinic, Mayo Clinic, University of Louisville. For more details: alchepnet.org

New publication 🚨 “Neighborhood Disadvantage and Access to Liver Transplant Referral for Severe Alcohol-Associated Hepatitis” by @LaurenNephewMD highlights disparities in transplant referral access. #HealthEquity #Hepatology

@juanpabloarab @ArunJSanyalVCU @nagachalasani @rajVuppaLanchi @DougSimonetto @Dr_Vijay_Shah @singal_ashwani @SamerGawrieh

🚨 New website update! The AlcHepNet website now has a refreshed design and expanded content. Learn more about our ongoing clinical trial and the investigators advancing alcohol-associated hepatitis research. Take a look 👇 alchepnet.org #ITAALD #ClinicalTrials

New in @Hepatology: In >218K U.S. patients, AUD pharmacotherapy was linked to fewer hospitalizations and lower alcohol-related costs —greatest savings in advanced liver disease.journals.lww.com/hep/abstract/9…

@juanpabloarab @ArunJSanyalVCU @Dr_Vijay_Shah @rajVuppaLanchi @nagachalasani @singal_ashwani

First post + big milestone! 🎉 The ITAALD Trial has officially enrolled its first patient in January. Huge thanks to our investigators and site teams for making this happen. We’re just getting started. #ITAALD #ClinicalTrials